Bio-Path Holdings to Announce Third Quarter 2018 Financial Results on November 15, 2018

HOUSTON, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., BPTH, a biotechnology company leveraging its proprietary DNAbilize^® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Thursday, November 15, 2018 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2018 and to provide a business overview.

To access the live conference call, please call (844) 815-4963 (domestic) or (210) 229-8838 (international) at least five minutes prior to the start time and refer to conference ID 8564777. A live audio webcast of the call will also be available on the Events section of the Company's website, www.biopathholdings.com. An archived webcast will be available on the Bio-Path website approximately two hours after the event. 

About Bio-Path Holdings, Inc.

Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path's lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers and in preclinical studies for solid tumors. This is followed by BP1002, targeting the Bcl-2 protein, which the company anticipates entering into clinical studies where it will be evaluated in lymphoma and solid tumors.

For more information, please visit the Company's website at http://www.biopathholdings.com.  

Contact Information:
                                   
Investors

Will O'Connor
Stern Investor Relations
212-362-1200
will@sternir.com 

Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369